Panel Discussion: From Exploratory Signal to Regulatory Confidence: Building the Evidence Base for MRD as an Approved Endpoint

• Outlining the evidence regulators expect for ctDNA endpoint consideration, including how multiple myeloma secured its first approval
• Identifying gaps between exploratory biomarker use and surrogate endpoint qualification
• Positioning ctDNA endpoints for inclusion in regulatory dialogue and submission packages

Speakers:

Brian Baker

Exec Dir

Regeneron

Diana Vega

Global Senior Director, Early Detection

AstraZeneca

Dimple Modi

Senior Director - Oncology Precision Medicine

Regeneron Pharmaceuticals

Abde Abukhdeir

Senior Director, Translational Regulatory Affairs, Oncology R&D

AstraZeneca